FibroBiologics wins European patent for Sox9 gene therapy to regenerate cartilage
FBLG•European patent covers Sox9-based cartilage regeneration therapy
FibroBiologics won a European patent for Sox9-based gene therapy that converts fibroblasts into cartilage-producing cells for cartilage repair.
The grant covers expression-vector compositions delivered to fibroblasts in or for joints, using viral or non-viral delivery systems.
The patent supports the company’s cartilage regeneration programs in orthopedics and degenerative disc disease.
European Patent No. EP 3043825 B1 includes 12 claims, with validation planned across selected European markets.
